Renal function, attributes and coagulation treatment in atrial fibrillation (R-FACT Study): retrospective, observational, longitudinal cohort study of renal function and antithrombotic treatment patterns in atrial fibrillation patients with documented eGFR in real-world clinical practices in Germany.
OBJECTIVE
This retrospective, observational, longitudinal study aimed to document the distribution, changes in renal function [measured by estimated glomerular filtration (eGFR)] and antithrombotic treatment pattern in atrial fibrillation (AF) patients in real-world settings managed by general practitioners in Germany.


RESULTS
Data were extracted from the German Longitudinal Patient Database. A total of 15,900 patients with AF were identified. Among 1660 having eGFR available at baseline, 3.4% had severely impaired eGFR, 9.7% and 25.6% had moderate severe decrease and moderate decrease in eGFR, respectively, and 61.3% had mildly decreased/normal eGFR. Patients with moderately and severely decreased eGFR tended to be older. The proportion of patients with a CHADS2 score ≥ 2 was 92.9% in those with severely decreased eGFR, and 87.0% and 79.1% in those with moderately severe and moderately decreased eGFR. During follow up, 52.1% of patients with severely decreased eGFR, and 26.3% to 23.7% of patients with moderately decreased eGFR were not treated by antithrombotic. When comparing baseline with follow-up eGFR, 55.0% of patients showed decreased eGFR. Age, diabetes, dyslipidaemia and history of myocardial infarction were identified as significant predictors for renal function deterioration based on results from multivariate Cox regression model.


CONCLUSIONS
Moderate-to-severe renal dysfunction is prevalent (~38%) in German AF patients with documented eGFR managed in actual clinical practices. The risk of stroke, as measured by the CHADS2 score, was associated with decreased renal function. Treatment with anticoagulation therapies decreased with decreasing renal function, despite increasing risk of stroke. Anticoagulation treatments remain suboptimal during the 12-month follow up in patients with moderate or severe renal impairment.
Global Health Outcomes, Merck & Co., Inc., Whitehouse Station, NJ, USA.
D
D
Wu
G
G
Mansoor
C
C
Kempf
M-S
MS
Schwalm
J
J
Chin
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000188:drug therapy*; D015331:Cohort Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005858:Germany; D005919:Glomerular Filtration Rate; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000150:complications*; D012189:Retrospective Studies; D012307:Risk Factors
D005343:Fibrinolytic Agents